RA and GMP 13 Risk Management 2024

Regulatory Affairs and GMP compliance Risk Management

Medicines Safety: Benefits and Risks

  • General Principle

    • No effective medicine is without risk; every medicine may have side effects.

    • Benefits should be weighed against risks for individual patients.

    • Consultation with healthcare professionals (e.g., doctor, pharmacist) is crucial for establishing an acceptable benefit-risk balance.

Medicines Safety: Ongoing Evaluation

  • Limitations of Clinical Trials

    • Not all safety issues are identified during pre-market trials.

    • Real-life use involves larger, diverse patient populations and prolonged use.

    • Differences in age, severity of disease, and concurrent medications can affect safety outcomes.

Importance of Monitoring

  • Continuous monitoring and evaluation of medicines is vital throughout their lifecycle.

  • Ensure the benefit-risk balance remains positive for patients over time.

Regulatory Framework: PRAC

  • Establishment of PRAC

    • In July 2012, the Pharmacovigilance Risk Assessment Committee (PRAC) was introduced in Europe.

    • PRAC specifically advises on safety issues related to medicines in the EU.

Risk Management Plan (RMP)

  • Overview

    • Since July 2012, all new medicinal products must have an RMP.

    • RMP focuses on assessing and minimizing important risks throughout the product's lifecycle.

Managing Risks

  • Risks can be managed through:

    • Including warnings in product information (SmPC and PIL).

    • Proper labelling of the product.

Additional Measures for Safety

  • When necessary, further actions can inform healthcare professionals and patients about specific risks.

Communication Strategies

  • Examples of measures to keep healthcare professionals and patients informed include:

    1. Writing directly to healthcare professionals.

    2. Providing educational materials and tools.

    3. Recommending specific tests to recognize side effects early and mitigate them.

Details of the Risk Management Plan (RMP)

  • Definition and Purpose

    • An RMP describes current knowledge about the safety and efficacy of a medicinal product.

    • Provides plans for further studies on safety and efficacy.

    • Outlines measures to prevent/minimize risks associated with the medicine.

Regulatory Requirements for RMP

  • Marketing Authorisation Holders

    • Required to submit an RMP for any new medicinal product for human use at the time of application.

    • For nationally authorized products, RMPs must be submitted to the HPRA for approval.

Post-Marketing Safety Studies

  • The RMP may include plans for post-authorisation safety studies to gain more information on specific safety aspects.

  • Ensuring access to quality information for patients, consumers, and healthcare professionals about benefits and risks is essential.

  • The SmPCs and PILs for medicines authorized in Ireland and the EU are available on HPRA and EMA websites.